| abstract |
REFERS TO NEW BENZOATE DERIVATIVES OF 1,3,4-OXADIAZOL-2 (3H) -ONE OF FORMULA I, WHERE R IS -NR1R2, -NR1R2R3X; X IS ANION CONTRARY OR NEGATIVE; R1 AND R3 ARE H or C1-C4 ALKYL; R2 IS H, C1-C4 ALKYL, DI (C1-C4 ALKYL) AMINOETHYL or R1 AND R2 FORM A HETEROCYCLE LIKE MORPHOLINE, PIPERIDINE, PIPERAZINE AND N- (C1-C4 ALKYL). PREFERRED COMPOUNDS 4 - [(DIETHYLAMINE) METHYL] BENZOATE 4-CHLORO-2 - [[5- [4- (TRIFLUOROMETIL) PHENYL] -2,3-DIHYDRO-2-OXO-1,3,4- OXADIAZOL-3-IL] METHYL] PHENYL; 4 - [(4-MORPHOLINYL) -MEthyl] BENZOATE 4-CHLORO-2 - [[5- [4- (TRIFLUOROMETHYL) PHENYL] -2,3-DIHYDRO-2-OXO-1,3,4- OXADIAZOL-3-IL] METHYLPHENYL, AMONG OTHERS. COMPOUND I IS A LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNELS MODULATOR AND MAY BE USEFUL IN THE PROTECTION OF NEURAL CELLS AND TREATMENT OF DISEASES ARISING FROM POLARIZATION AND CONDUCTANCE DYSFUNCTION, SUCH AS ISCHEMULAR MEMBRANE. APOPLETIC SEIZURES, SEIZURES, EPILEPSY, ASTHMA, IRRITABLE BOWEL SYNDROME, MIGRANE, TRAUMATIC CELL DAMAGE, SPINAL CELL DAMAGE, MALE ERECTILE DYSFUNCTION, URINARY INCONTINENCE |